Raleigh, N.C.-based Merz said the DeScribe device has FDA 510(k) clearance and CE Mark approval in the European Union for the device, and that the patch will be folded into its aesthetics portfolio.
“The addition of ONOnLight Sciences’ innovative technology allows us to better meet the needs of aesthetic practices that focus on energy-based devices. We have a vision to be the most innovative company in aesthetics, and this acquisition clearly complements our growing and diversified global portfolio, which includes the Ultherapy and Cellfina devices,” Merz Pharma CEO Philip Burchard said in a press release.
The DeScribe Transparent PFD patch is designed to be placed over tattoos prior to irradiation to enable rapid multiple laser passes in a single treatment session, Merz said.
“Merz North America’s robust aesthetic portfolio continues to strategically grow through innovative products addressing conditions with fast growing demand such as tattoo removal. This latest addition to our offerings underscores the strong commitment we have to growing our US business by responding quickly to market demands,” Merz North America prez and CEO Bill Humphries said in prepared remarks.
Merz said the patch also provides “significant optical clearing of tissue,” protects the epidermis and “inhibits potentially infectious back-splatter and fumes,” according to a press release.
“We look forward to joining Merz and expanding awareness and use of the DeScribe Transparent PFD Patch. We share Merz’s commitment to innovation that directly and positively impacts patient health and welcome the opportunity to be part of its strong product line-up,” ON Light Sciences prez & CEO David Sell said in a prepared statement.
“Merz continues to actively seek opportunities to partner with or acquire companies such as ON Light Sciences. Through a focused corporate development strategy and our Merz Corporate Venture Capital Initiative, we remain actively engaged in funding innovative and category-building technologies within the aesthetics space,” Hans-Jörg Bergler, Head of Corporate Development for Merz Pharma Group. “